Top-News

Rein Therapeutics Aktie News

Aktie
WKN:  A3DZ0Z ISIN:  US00887A2042 US-Symbol:  RNTX Branche:  Biotechnologie Land:  USA
1,36 $
-0,03 $
-2,16%
1,168 € 05.12.25
Depot/Watchlist
Marktkapitalisierung *
18,11 Mio. €
Streubesitz
65,53%
KGV
0,00
Index-Zuordnung
-

Rein Therapeutics News

24.06.25 - PR Newswire
Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders
Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders PR Newswire
27.05.25 - PR Newswire
Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF
Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF PR Newswire
19.05.25 - PR Newswire
Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference
Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference PR Newswire
15.05.25 - PR Newswire
Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update PR Newswire
12.05.25 - PR Newswire
Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF
Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF PR Newswire
01.05.25 - PR Newswire
Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF
Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-​Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF PR Newswire
30.04.25 - PR Newswire
Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025
Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025 PR Newswire
28.04.25 - PR Newswire
Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference
Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference PR Newswire
23.04.25 - PR Newswire
Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases
Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases PR Newswire
15.04.25 - PR Newswire
Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F
Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-​fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F PR Newswire
07.04.25 - PR Newswire
Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update PR Newswire
10.01.25 - PR Newswire
Aileron Therapeutics Announces Rebranding to Rein Therapeutics
Aileron Therapeutics Announces Rebranding to Rein Therapeutics PR Newswire

Newssuche

Videos

newspaper
05.12.25 +1,73%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »